Skip to content

Finding new treatments and hope through clinical trials in Quebec

Clinical trials represent a vital gateway in the quest for new medical treatments and therapies, offering a beacon of hope for patients battling sarcoma in Quebec. These studies are meticulously designed to evaluate the efficacy, safety, and overall effectiveness of innovative medical interventions, such as drugs and vaccines, within a cohort of human participants. By rigorously assessing these interventions, clinical trials ensure that they are not only effective but also safe for use in sarcoma patients.

Participation in clinical trials plays a pivotal role in propelling the sarcoma medical community towards discovering groundbreaking treatment options. These trials set new benchmarks in the standard of care, benefiting both current and future patients. Moreover, engaging in a clinical trial grants patients the invaluable opportunity to access cutting-edge, state-of-the-art treatments that might be otherwise out of reach.

Below, you will find a comprehensive table summarizing the current list of clinical trials actively investigated by SaRC-Q physicians. These trials hold the promise of forging a brighter path in the journey to conquer sarcoma and offer renewed hope for those facing this formidable disease.

Clinical Trials Conducted by SaRC-Q Group

We invite you to explore the ongoing clinical trials conducted by the SaRC-Q group. If you are interested in participating in one of these groundbreaking trials, we encourage you to discuss with your oncologist. To connect with the trial investigator, please do not hesitate to reach out to the study coordinator.
Sarcoma SubtypeStudy Name & DescriptionPhaseSponsorParticipating HospitalsStatus
GISTAn International, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib
(INSIGHT)
IIIDeciphera Pharmaceuticals LLCMUHCUpcoming
Advanced Dedifferentiated LiposarcomaAn Open-Label, Single-Arm, Multi-Center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients with Treatment-naïve or Pre-treated Advanced Dedifferentiated LiposarcomaIIIBrightline-4/Boehringer IngelheimMUHCUpcoming
LeiomyosarcomaStudy of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)IIIPolaris PharmaceuticalsMUHCUpcoming
Advanced CancerA First in Human, Dose-Escalation Study of TORL-3-600 in Participants
with Advanced Cancer
ITORLMUHCUpcoming
Wild-type Solid TumorsAn Open-Label, Multi-Center Study to Investigate the Safety and Tolerability of SA53, an MDM2 Inhibitor, in Patients with Locally Advanced or Metastatic p53 Wild-type Solid Tumors (ACADIA)I
PI initiated MUHC
Upcoming
Advanced Solid TumorsTAK-676-1002 An Open-Label, Dose Escalation Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of TAK-676 As A Single Agent And In Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsITakedaJewish General Hospital
McGill University Health Centre
Upcoming
GISTPeak
A randomized trial of CGT9486+Sunitinib vs. Sunitinib in subjects with gastrointestinal stromal tumors
IIICogent BiosciencesMaisonneuve-Rosemont Hospital (HMR)Active
Open for recruitment
Tenosynovial Giant Cell TumorA Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell TumorIIIAbbisko TherapeuticsMUHCActive
Open for recruitment
RhabdomyosarcomaCOG-ARST2031
A Randomized Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
IIIChildren’s Oncology GroupMUHC
CHU Sainte-Justine
CHUQ
Active
Open for recruitment
Retroperitoneal Sarcoma A Randomized Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk Retroperitoneal Sarcoma (STRASS2)IIICCTG SR.7Maisonneuve-Rosemont Hospital (HMR)
MUHC
Active
Advanced Solid TumorsA Phase 1a/B Open-Label Master Study of Pf-07799544 As A Single-Agent And In Combination With Other Targeted Agents In Participants With Advanced Solid TumorsIPfizerJewish General Hospital
McGill University Health Centre
Centre intégré de cancérologie du CHU de Québec
Université Laval, Hôpital de l’Enfant-Jésus
Active
LeiomyosarcomaSUNRISE-LMS
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
II-IIIPTC TherapeuticsMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
Dedifferentiated LiposarcomaBrightline-1
A Study to Compare BI 907828 With Doxorubicin in People With Dedifferentiated Liposarcoma
II-IIIBoehringer IngelheimMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
GISTINTRIGUE
A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
IIIDeciphera Pharmaceuticals LLCMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
Desmoid TumorsA Randomized, Double-Blind, Placebo-Controlled Trial of Nirogacestat versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)IIISpring Works TherapeuticsMUHCActive
Closed for recruitment
Synovial Sarcoma
Myxoid Liposarcoma
IGNYTE-ESO
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
IIGlaxoSmithKlineMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
Synovial Sarcoma
Myxoid Liposarcoma
ZENITH-ESO
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
IGlaxoSmithKlineMaisonneuve-Rosemont Hospital (HMR)Active
Closed for recruitment
Tenosynovial Giant Cell TumorA Multicenter Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell TumorI-IIDeciphera Pharmaceuticals LLCMUHCActive
Closed for recruitment
Soft Tissue SarcomaA randomized controlled trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in patients with high-risk localized soft tissue sarcoma of the extremityIISARCMUHCActive
On hold
RhabdomyosarcomaARST-1431
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
IIINational Cancer Institute (NCI)MUHC
CHU Sainte-Justine
Closed